Pharmacogenomics News and Research

RSS

The terms pharmacogenomics and pharmacogenetics are often used interchangeably to describe a field of research focused on how genes affect individual responses to medicines. Whether a medicine works well for you—or whether it causes serious side effects—depends, to a certain extent, on your genes.

Researchers look at pharmacogenomics

When patients receive chemotherapy, 15 percent will have severe side effects while 85 percent will not - even though they're given the same relative dose.

28 Sep 2005

Possibility of tailored treatments for addiction based on how a person's genes behave

Scientists have learned how a genetic variation long suspected in making some people susceptible to alcoholism and narcotic drug addiction actually does so.

27 Sep 2005

Discovery of protein deficit that causes drug toxicity

Mayo Clinic researchers have discovered an inherited structural mechanism that can make drugs for some diseases toxic for some patients.

11 Jul 2005

New discovery sparks hope of safer dosage of Warfarin

The blood-thinning drug Warfarin tops the list of drug side-effects in Sweden. Patient sensitivity to Warfarin varies, which can lead to over-dosage and in certain cases to death.

17 May 2005

Pharmacogenomics used to treat inherited kidney disorder of children

Mayo Clinic researchers have used pharmacogenomics to develop a test and treatment for an inherited kidney disorder that can cause organ failure in children and young adults.

4 May 2005

Pattern of gene expression predicts multiple drug resistance, treatment failure in pediatric leukemia

The discovery of a specific pattern of gene expression linked to multiple-drug resistance of leukemic cells is giving researchers crucial information into why standard therapies fail to cure some children with acute lymphoblastic leukemia (ALL). This finding, from investigators at St. Jude Children’s Research Hospital, could lead to development of drugs that would overcome that resistance.

24 Apr 2005

Genes influence how heart failure patients respond to drugs

Genes dictate the color of our hair and eyes. They factor into whether we get cancer or heart disease. And, scientists increasingly recognize, they also ensure some patients will benefit from a prescription drug, while others develop adverse reactions or simply fail to respond at all.

21 Apr 2005

Gene expression pattern predicts multiple drug resistance

St. Jude Children's Research Hospital discovery of genetic links to multi-drug resistance gives clinicians new insight into the cause of treatment failure and suggests targets for novel anti-leukemic drugs

19 Apr 2005

Genomics and proteomics to increase the efficiency of drug discovery and development

While the United Sates is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to deploy genomics and proteomics as vital tools in drug discovery and development.

5 Apr 2005

New guidelines mean tailor-made drugs are on the way

Many experts believe a milestone has been reached with the issuing of guidelines for pharmaceutical companies to encourage them to gather and submit information about how genetic variations affect the way people respond to their drugs.

23 Mar 2005

Gene linked to bone mineral density

Sequenom has announced the discovery of a genetic variation in the gene encoding phosphodiesterase 4D (PDE4D) that is believed to affect osteoporosis risk. Fragility fractures caused by osteoporosis are a major cause of morbidity and mortality in the aging population.

23 Mar 2005

St. John's wort increases effectiveness of Plavix

The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds.

6 Mar 2005

Pharmacogenomics, has the potential to spark a major, technology-driven restructuring of the health care and pharmaceuticals industries

Pharmacogenomics, the study of genetic variability in the way individuals respond to medicines, has the potential to spark a major, technology-driven restructuring of the health care and pharmaceuticals industries

21 Dec 2004

Electrochemical DNA chip that is able to detect DNA at very low concentrations

Toshiba Corporation has announced the development of a highly sensitive electrochemical DNA chip that is able to detect DNA at very low concentrations, a capability that will support advances in gene detection and analysis for individual treatment regimes, and the monitoring of healthy individuals for any predisposition to certain diseases.

6 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Grant to study genetics and drug interaction

A University of Minnesota researcher received a nearly $1 million grant from the National Institutes of Health (NIH) to study how genetic differences affect whether people will experience dangerous drug interactions and how to adjust medications to avoid those interactions.

10 Sep 2004

Nighttime surge of ghrelin may point to new targets for treating obesity

UCLA scientists have discovered that lean people experience a huge nighttime surge of ghrelin — the hormone that stimulates hunger — but obese people do not.

29 Jun 2004

New statistical techniques for cancer diagnosis

CSIRO statisticians have developed a new way to subtype paediatric Acute Lymphoblastic Leukaemia (ALL), the most common form of cancer in children under 12.

9 Jun 2004

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

A chemotherapy regimen commonly used to treat non-small cell lung cancer is both more effective and more toxic in Japanese patients than in American patients, researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

7 Jun 2004

New generation drug therapy targets the individual

The days of ‘one size fits all’ medicines may soon be a thing of the past for people undergoing radical drug therapies for chronic or serious illnesses.

5 Jun 2004